Depemokimab Receives Positive CHMP Opinion for Severe Asthma With Type 2 Inflammation and Chronic Rhinosinusitis With Nasal Polyps
December 13, 2025
December 13, 2025
LONDON, England, Dec. 13 -- GSK (formerly GlaxoSmithKline), a biopharmaceutical company, issued the following news release on Dec. 12, 2025:
* * *
Depemokimab receives positive CHMP opinion for severe asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps
- If approved, depemokimab will be the first and only ultra-long-acting biologic in the EU to treat respiratory diseases
- Positive opinion based on four phase III trials . . .
* * *
Depemokimab receives positive CHMP opinion for severe asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps
- If approved, depemokimab will be the first and only ultra-long-acting biologic in the EU to treat respiratory diseases
- Positive opinion based on four phase III trials . . .